Guardant Health(GH) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $281 million, representing a 39% year-over-year growth, while full-year revenue reached $982 million, a 33% increase year-over-year [9][31] - Non-GAAP gross margin improved to 66% in Q4 2025, up from 63% in the prior year, driven by a significant reduction in Reveal cost per test [32][33] - Adjusted EBITDA loss improved to $64.9 million in Q4 compared to $78.4 million in the prior year quarter [34] Business Line Data and Key Metrics Changes - Oncology revenue increased 30% to $190 million in Q4, with volumes growing 38% to approximately 79,000 tests [9][29] - Screening revenue totaled $35 million from approximately 38,000 Shield tests in Q4, reflecting strong sequential growth [19][30] - Biopharma and data revenue grew 18% year-over-year to $210 million in 2025 [16][17] Market Data and Key Metrics Changes - Guardant360 Liquid volumes increased nearly 30%, supported by expanding clinical utility from Smart apps launched over the past year [30] - Reveal continued to be the fastest-growing oncology product, benefiting from CRC surveillance reimbursement and early uptake for late-stage therapy response monitoring [12][30] - Shield's adherence rate reached 93% across the first 100,000 tests ordered, significantly higher than other screening modalities [22] Company Strategy and Development Direction - The company aims to expand Shield to include multi-cancer detection results, enhancing its market position [24] - Strategic collaborations with Quest Diagnostics and PathGroup are expected to broaden national reach and enhance commercial infrastructure [23] - The acquisition of MetaSyte Diagnostics is anticipated to enhance the oncology product portfolio and accelerate multi-disease detection capabilities [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, expecting revenue growth of 27%-30% and oncology revenue growth of 25%-27% [36][37] - The company is focused on achieving cash flow breakeven by the end of 2027, with expectations of positive free cash flow from the core business in 2026 [35][40] - Management highlighted the importance of reimbursement wins for therapy monitoring as a significant growth driver for the oncology business [46] Other Important Information - The company reported a significant increase in the commercial team, with approximately 300 sales representatives by the end of 2025 [21] - The ADLT reimbursement rate for Shield is set at $1,495, secured through December 2027, supporting healthy ASP and gross profit [25][39] - The company is actively pursuing FDA approvals for new products, including Guardant360 Liquid CDx for lung cancer [40] Q&A Session Summary Question: Can you elaborate on Reveal therapeutic monitoring and its opportunity? - Management expressed excitement about Reveal for therapy monitoring, emphasizing its synergy with Guardant360 for patient treatment decisions [44][46] Question: How should we think about oncology growth throughout the year? - Management is bullish about 2026, expecting at least 20% growth in Guardant360 volumes and strong performance from Reveal [50][51] Question: What is the expected burn for Shield in 2026? - The company anticipates a similar burn for screening as in 2025, around $220 million, while the rest of the business is expected to be cash flow positive [54][55] Question: What is the latest thinking on ADLT pricing for Guardant360? - Management indicated that no ADLT pricing is baked into the 2026 guidance, with expectations for FDA submission in H2 2026 [59][61] Question: Can you discuss the opt-in rate for MCED Shield and its potential for FDA approval? - Management reported good adoption rates for the MCED offering, with enthusiasm from providers and patients, but did not provide specific numbers [76][78]